极早产或极低出生体重儿青春期晚期及成年早期的呼气气流:个体参与者数据荟萃分析
该研究汇集11项队列的个体数据,比较极早产(<32周)或极低出生体重(<1501g)者与正常出生体重或足月对照在青春期晚期及成年早期的最大呼气气流。平均21岁时,极早产/极低出生体重组的FEV1、FVC、FEV1/FVC及FEF25-75%的Z评分均显著低于对照组,提示其气道生长潜力未达充分,后期慢阻肺风险可能增加。
要点
- 该人群FEV1、FVC及FEF25-75%的Z评分也显著低于足月或正常出生体重对照。
- 临床应关注该人群成年早期肺功能追踪,警惕慢阻肺风险。
核心结论
- 极早产或极低出生体重者在青春期晚期和成年早期未达到最大气道生长潜力,后期慢阻肺风险可能增加。
研究设计与样本
- 个体参与者数据荟萃分析,纳入11项队列研究,共935例极早产或极低出生体重者和722例对照。
- 呼气流量变量转换为Z评分,采用广义线性混合模型一步法分析。
主要发现
- 低于第5百分位数的个体比例比较也呈现相似模式。
临床怎么用
- 对极早产或极低出生体重儿在青春期晚期及成年早期应关注肺功能监测,评估气流受限。
- 临床可考虑将此类人群视为慢阻肺高危人群,加强长期随访和早期干预。
局限性
- 研究数据多来自表面活性物质使用前的时代,可能不完全反映当前诊疗背景下出生人群的特征。
- 排除了仅纳入支气管肺发育不良等高度选择队列的研究,可能影响结果的外推性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Maximal expiratory airflow peaks early in the third decade of life, then gradually declines with age. The pattern of airflow through adulthood for individuals born very preterm (at <32 weeks' gestation) or with very low birthweight (<1501 g) is unknown. We aimed to compare maximal expiratory airflow in these individuals during late adolescence and early adulthood with that of control individuals born with normal birthweight (>2499 g) or at term. METHODS: We did a meta-analysis of individual participant data from cohort studies, mostly from the pre-surfactant era. Studies were identified through the Adults born Preterm International Collaboration and by searching PubMed and Embase (search date May 25, 2016). Studies were eligible if they reported on expiratory flow rates beyond 16 years of age in individuals born very preterm or with very low birthweight, as well as controls born at term or with normal birthweight. Studies with highly selected cohorts (eg, only participants with bronchopulmonary dysplasia) or in which few participants were born very preterm or with very low birthweight were excluded. De-identified individual participant data from each cohort were provided by the holders of the original data to a central site, where all the data were pooled into one data file. Any data inconsistencies were resolved by discussion with the individual sites concerned. Individual participant data on expiratory flow variables (FEV1, forced vital capacity [FVC], FEV1/FVC ratio, and forced expiratory flow at 25-75% of FVC [FEF25-75%]) were converted to Z scores and analysed with use of generalised linear mixed models in a one-step approach. FINDINGS: Of the 381 studies identified, 11 studies, comprising a total of 935 participants born very preterm or with very low birthweight and 722 controls, were eligible and included in the analysis. Mean age at testing was 21 years (SD 3·4; range 16-33). Mean Z scores were close to zero (as expected) in the control group, but were reduced in the very preterm or very low birthweight group for FEV1 (-0·06 [SD 1·03] vs -0·81 [1·33], mean difference -0·78 [95% CI -0·96 to -0·61], p<0·0001), FVC (-0·15 [0·98] vs -0·38 [1·18], -0·25 [-0·40 to -0·10], p=0·0012), FEV1/FVC ratio (0·14 [1·10] vs -0·64 [1·35], -0·74 [-0·85 to -0·64], p<0·0001), and FEF25-75% (-0·04 [1·10] vs -0·95 [1·47], -0·88 [-1·12 to -0·65], p<0·0001). Similar patterns were observed when we compared the proportions of individuals with values below the fifth percentile. INTERPRETATION: Individuals born very preterm or with very low birthweight are at risk of not reaching their full airway growth potential in adolescence and early adulthood, suggesting an increased risk of chronic obstructive pulmonary disease in later adulthood. FUNDING: National Health and Medical Research Council (Australia), University of Bergen, Western Norway Regional Authority, National Institute for Health Research (UK), Stichting Astmabestrijding, St Olav's Hospital's Research Fund, Academy of Finland, European Commission, National Institute of Child Health and Human Development (USA), Victorian Government's Operational Infrastructure Support Program.
引用
- Doyle LW, Andersson S, Bush A, et al. Expiratory airflow in late adolescence and early adulthood in individuals born very preterm or with very low birthweight compared with controls born at term or with normal birthweight: a meta-analysis of individual participant data. Lancet Respir Med. 2019. PMID: 31078498. doi:10.1016/S2213-2600(18)30530-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。